Search
Lopinavir
go.drugbank.com/drugs/DB01601ApprovedInvestigational[saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself … [A191757] Lopinavir was previously under investigation in combination with ritonavir for the treatment of COVID-19 caused by SARS-CoV-2.[L12012]
Elasomeran
go.drugbank.com/drugs/DB15654ApprovedInvestigational[L39160, L39277] A similar booster dose is also available in the US for patients 18 years of age and older. … [L12660] This trial was later followed by phase II and III trials, where the Moderna COVID-19 Vaccine demonstrated vaccine efficacy of 94.1%.
Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]
Betahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigational[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It is currently marketed in Canada by various companies, including Teva Pharmaceuticals.
Omega-3 fatty acids
go.drugbank.com/drugs/DB11133ApprovedInvestigationalNutraceuticalOmega-3 fatty acids play a critical role in metabolism and cellular function and they are available as daily supplements. On September 8, 2004, the U.S. … α-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that originally come from microalgae that is further consumed by
Cannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalOn June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. … CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex.
Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigationalTaletrectinib is an orally available small molecule kinase inhibitor. … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]
Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigational[L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence
Cryptenamine
go.drugbank.com/drugs/DB00785ApprovedIt has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.
Amoxapine
go.drugbank.com/drugs/DB00543ApprovedIn non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood.